Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EpiCor
- Development stage
- Unknown
- Lead developer
- Cargill
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
EpiCor is a whole food fermentate (postbiotic) derived from the yeast *Saccharomyces cerevisiae*. It is produced through a proprietary fermentation and drying process by Embria Health Sciences, a subsidiary of Cargill. Unlike traditional yeast extracts or purified beta-glucans, EpiCor contains a complex profile of metabolites, including proteins, fibers, polyphenols, vitamins, and amino acids. It is primarily marketed as a dietary supplement for immune support and respiratory health. Clinical research indicates that EpiCor modulates the immune system by increasing secretory IgA levels, enhancing natural killer (NK) cell activity, and supporting a balanced inflammatory response. It is widely used as an ingredient in various health and wellness formulations.
- Brand names
- EpiCor
- Other names
- Saccharomyces cerevisiae fermentateyeast fermentatedried yeast fermentate
02
Targets
CD4 (T lymphocyte surface antigen)sIgA (Secretory immunoglobulin A)
Beyond the preview
Go deeper on EpiCor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpiCor.